23 March, 2020

Transmed Pharma Acquires Marketing Authorization for Konakion

Ramallah, March 23, 2020 – Transmed Pharma has just received marketing authorization for Konakion in Palestine as a result of worldwide transfer of its marketing and distribution rights from Roche to Cheplapharm. Konakion contains the active ingredient Phytomenadione, also called Vitamin K1, and is used to prevent or treat bleeding due to low levels of Vitamin K in newborns as well as adults.

Late HDNB (Hemorrhagic Disease of the Newborn) occurs in five to seven of 100,000 live births without vitamin K prophylaxis and results in death or severe disability in 33% of affected newborns. Konakion is the only form of Vitamin K available in the Palestinian market for many years, designed specifically for oral as well as intramuscular use.

About Cheplapharm
Cheplapharm is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, Cheplapharm achieves sustainable annual growth rates. Cheplapharm has been one of the fastest-growing pharmaceutical companies in Europe for years with annual sales of 650 million euros in 2020.

Please click here for more information.

Back Next